<DOC>
	<DOCNO>NCT00001181</DOCNO>
	<brief_summary>The normal change puberty , breast enlargement , pubic hair menstrual period , usually begin age 9 15 response hormone produce body . Some child 's body produce hormone normal age start puberty early . This condition know precocious puberty . The hormone responsible onset puberty come pituitary gland ovary . The hormone pituitary gland act ovaries produce different hormone cause breast grow , pubic hair develop , menstruation . Many child precocious puberty treat medication know lutenizing hormone-releasing hormone analog ( Lupron , Histerelin , Deslorelin ) . This drug make laboratory design act like natural hormone LHRH , make pituitary gland . The drug cause pituitary gland decrease amount hormone release thereby decrease amount hormone release ovary . However , girl already low level pituitary hormone yet ovary still produce hormone . Researchers believe LHRH analog therapy work child . Testolactone drug act directly ovary . It work prevent last step estrogen production ovary . The goal treatment stop estrogen production delay onset puberty normal age . Researchers give patient LHRHa resistant precocious puberty Testolactone six month . If initial treatment successful patient experience bad side effect , continue receive medication puberty desire . Throughout therapy patient receive frequent monitoring general state health , hormone level , medication level .</brief_summary>
	<brief_title>Testolactone Treatment Girls With LHRH Resistant Precocious Puberty</brief_title>
	<detailed_description>Females precocious puberty low level serum gonadotropin high level serum estrogen , demonstrate inadequate clinical response therapy luteinizing hormone release hormone analog ( Lupron , Histerelin , Deslorelin ) , treat testolactone . Testolactone inhibits aromatase , last enzyme estrogen biosynthesis . The goal treatment inhibit estrogen secretion thus delay secondary sexual maturation epiphyseal closure normal age . The intent alleviate psychological problem short stature frequently associate disorder . Throughout therapy , patient receive frequent clinical , hormonal , toxicological monitoring . The initial treatment period six month . If patient respond treatment tolerate well , testolactone give puberty desire . Patients exhibit pubertal level serum gonadotropins testolactone therapy , indicate onset secondary , gonadotropin-dependent puberty , receive LHRH analog addition testolactone .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Fibrous Dysplasia Bone</mesh_term>
	<mesh_term>Fibrous Dysplasia , Polyostotic</mesh_term>
	<mesh_term>Testolactone</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients girl age 18 year ( entry study ) gonadotropinindependent precocious puberty . All ethnic group include . EXCLUSION CRITERIA : Males exclude , patient clinicallysignificant hepatic and/or renal impairment ( testolactone metabolize via liver kidney ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>McCune-Albright Syndrome</keyword>
	<keyword>Aromatase Inhibitor</keyword>
	<keyword>Teslac</keyword>
</DOC>